← Back to headlines
Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy
Novavax has projected a 2026 revenue target of $230 million to $270 million, supported by a new partnership with Pfizer and a cost reduction strategy.
26 Feb, 20:09 — 26 Feb, 20:09
Sources
Showing 1 of 1 sources
